Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31461381.
- Also identified by DOI 10.1200/JCO.19.01623.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<i>The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.</i>
Medical subject headings
- Drug-Related Side Effects and Adverse Reactions
- Immunotherapy